Regeneron Rallies After Seeking Emergency-Use Approval For Antibody Cocktail Hailed As "Cure" By Trump

Shares of Regeneron are ripping higher Thursday in premarket trading, building on its gains from Wednesday evening, after the company submitted its COVID-19 antibody cocktail to the FDA for emergency-use approval.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.